Lipid/Metabolic
New meta-analysis: Statins of benefit in primary prevention
9 COMMENTS - Jun 30, 2009 19:01 EDT
A new meta-analysis including some of the more contemporary statin trials has found that the agents significantly improve survival and reduce coronary and cardiovascular end points in primary-prevention populations, a benefit that extends to all subgroups. But the exact cost/benefit equation for each group remains to be determined.

Rotterdam, the Netherlands - Use of statins is associated with significantly improved survival and large reductions in the risk of major cardiovascular events in patients who have risk factors but who do not have established cardiovascular disease, according to a new meta-analysis of major statin trials published online June 30 in BMJ [1].

It shows that the relative risk reduction from long-term statin use in a primary-care setting is comparable to that observed in secondary prevention and confirms the results of the JUPITER study regarding the beneficial effects of statins across a range of patient groups, say the researchers.Read full article »

Inside: Lipid/Metabolic
Accredited educational programs, supported by industry, developed by theheart.org

More
Lipid/Metabolic
Reducing CV Risk: What Add-On Therapies Do You Use?
5 COMMENTS - Jan 27, 2009 15:53 EST
Reducing CV Risk: What Add-On Therapies Do You Use? Click to take the survey and compare answers. The results will help us create future CME programming
More
Lipid/Metabolic
A Canadian Perspective on the SEAS Trial
Sep 8, 2008 10:00 EDT
Navigating the SEAS: Join Drs Fitchett and Chan as they present their views on the latest controversial findings from clinical on treating aortic stenosis with statins alone or in combination with ezetimibe.
 
heartbriefs
Alogliptin delayed; cancer concerns with insulin glargine
1 COMMENT - Jun 30, 2009 15:15 EDT
The makers of alogliptin say it will be two years before they have the cardiovascular data needed by the FDA, while the EASD raises concerns over a possible cancer risk with insulin glargine.
Hypertension
Wolves in sheep's clothing: Don't ignore white-coat and masked hypertension
1 COMMENT - Jun 29, 2009 16:00 EDT
White-coat hypertension and masked hypertension should not be regarded as benign, say the authors of a new 10-year study. The risk of developing sustained hypertension is higher in people with the above two conditions than in those who have normal blood pressure, they found.
Prevention
Moderate wine, little meat, many vegetables may be key Mediterranean diet items linked to longer life
8 COMMENTS - Jun 25, 2009 14:30 EDT
A population-based cohort study of individuals in Greece has teased out items in the Mediterranean diet that appear to contribute to the increased longevity associated with this diet.
heartbriefs
Intensive LDL lowering improves carotid plaque stability
3 COMMENTS - Jun 24, 2009 16:30 EDT
Investigators report that echogenicity, an ultrasound-based measure of plaque stability, was significantly improved among patients treated to very low LDL-cholesterol levels.
Hypertension
"Natural" ED product recalled; contains PDE-5 inhibitor
Jun 22, 2009 16:00 EDT
People taking the nonprescription dietary supplement marketed under the name Stamina-Rx "should stop using it immediately," the FDA is warning consumers.
Lipid/Metabolic
More patients at LDL targets, but improvement still needed
Jun 22, 2009 16:00 EDT
Compared with a decade ago, where just 38% achieved LDL-cholesterol guideline targets, 73% of individuals are now at goal.
Clinical cardiology
Psoriasis associated with all vascular disease
5 COMMENTS - Jun 22, 2009 13:45 EDT
As well as being an independent risk factor for cardiovascular disease, psoriasis is also associated with an increased risk of cerebrovascular disease and peripheral arterial disease, a new case-control study has shown.
Hypertension
New low-cost, solar-powered BP device for developing countries
Jun 18, 2009 15:15 EDT
A new, low-cost, solar-powered blood-pressure-monitoring device has been shown to be accurate and easy to use and was well accepted by healthcare professionals and patients in a field trial in Africa. This could be a "critical tool" in tackling the global problem of hypertension, said one expert.
Hypertension
A Portuguese success story: One nation begins to curb its salt intake
6 COMMENTS - Jun 18, 2009 10:00 EDT
Doctors from the Portuguese Society of Hypertension have spearheaded a unique mass-media campaign about the harmful consequences of consuming too much salt, which in turn has led to the Portuguese Parliament approving a law restricting the sodium content of processed foods.
Heart failure
NT-proBNP proposed for LVD screening in patients at high risk for heart failure
Jun 17, 2009 13:00 EDT
The natriuretic peptide had a very high negative predictive value for identifying LV dysfunction in asymptomatic diabetics and hypertensives in an observational study.
Murmurs
theheart.org editor wins NIHCM journalism award
3 COMMENTS - Jun 16, 2009 13:00 EDT
Shelley Wood, managing editor of theheart.org, has won a 2009 National Institute for Health Care Management Journalism and Research Award for her "Myxo ring mix-up" series.
Educational partnerships
Lipid/Metabolic
What happened at AHA 2008?: The Baylor College of Medicine Perspective
Dec 11, 2008 12:00 EST
Join Drs Ballantyne and Nambi as they discuss the Jupiter Trial and what was hot at AHA 2008 in lipids and prevention.
View all »
Editorial Programs
Editorial series
Getting to the bottom of BARI 2D
Jun 25, 2009 00:03 EDT
Join Drs Valentin Fuster, William E Boden, and George D Dangas as they discuss the results, plus the evolution of therapy over the last forty years, the mechanisms of coronary artery disease progression in diabetic patients, and what is perhaps one of the most fundamental problems in the field: that patients today are still not treated to target with best medical therapy.
Editorial series
Life and times of leading cardiologists with Rob Califf. Guest: Steve Nissen
1 COMMENT - Jun 1, 2009 10:20 EDT
Join Dr Robert Califf for a probing and personal interview with Dr Steven Nissen, about his activist days at the University of Michigan and the development of IVUS, to how he ended up at the Cleveland Clinic and what he thinks about the future of medicine in America.
The Cardiology Show
ACC 2009: From the eye of the storm in Orlando
Apr 2, 2009 15:35 EDT
Join Drs Valentin Fuster, Anne Curtis, Timothy Gardner, Barry Greenberg, Cindy Grines, Bob Harrington, Sanjay Kaul, Harlan Krumholz, and Salim Yusuf as they unravel the STICH trial and debate the lessons learned from PROTECT-AF in Part 1 of the Cardiology Show. In Part 2 of the program, the JUPITER trial is back on the table and our experts give their opinion on the polypill following the results of the TIPS study.
button
Previews
View all CME programs >>
View all »
Info from Industry
Promotional educational programs

Resource center
LIPID/METABOLIC
A venue for information, slides, articles, tools, and support material for physicians and healthcare providers.
Poll
Do the latest postmarketing surveillance data reassure you about the risk of cancer with ezetimibe?
See: Michael O'Riordan. FDA postmarketing surveillance data show no cancer risk with ezetimibe.
Yes
No

Vote